ThinkstockNow that Pfizer Inc. (NYSE: PFE) has started to sell Viagra online at Viagra.com, can Cialis.com and Levitra.com be far behind? These two other drugs face the same black market trouble Viagra does. Pfizer…
ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating billions upon billions in annual sales in the United States alone. Some of these…
Wikimedia CommonsMen, or their significant others, will be able to buy Pfizer Inc.’s (NYSE: PFE) erectile dysfunction drug Viagra online soon. Maybe the big pharmaceutical company figures it is easier to use a computer than…
ThinkstockDrug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) has withdrawn its application for European regulatory approval of its weight-loss drug Belviq. The drug was approved for use in the United States last June. Arena made…
Biotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what investors need…
ThinkstockBiotech investing has always proven to be a slippery slope. It is one thing to own one of the large-cap biotech stocks, but it can be a challenge when looking for the stocks that have…
ThinkstockDrug giant Pfizer Inc. (NYSE: PFE) this morning reported adjusted earnings and revenues that missed analysts estimates, and the stock is down more than 3%. Last week competitor Amgen Inc. (NASDAQ: AMGN) also missed…
ThinkstockAbbVie Inc. (NYSE: ABBV) reported first-quarter 2013 results before markets opened this morning. The pharmaceutical research firm posted adjusted diluted earnings per share (EPS) of $0.68 on revenues of $4.33 billion. Total sales were…
Wikimedia CommonsWe have now seen three Dow Jones Industrial Average components raise their dividend payouts to shareholders this week. The third is Johnson & Johnson (NYSE: JNJ), which has just declared an increase in…
ThinkstockVIVUS Inc. (NASDAQ: VVUS) is the king of weight loss drugs now that it is operating with the first pill to help assist weight loss in a decade. The company’s Qsymia recently received an…
ThinkstockBiotech pipeline news and biotech drug news continues to hit. A report from Bank of America/Merrill Lynch is highlighting four small-cap to mid-cap biotech stocks with positive prescription trends so far in 2013. The analyst…
ThinkstockAbbott Laboratories (NYSE: ABT) reported first-quarter 2013 results before markets opened this morning. The drugmaker reported adjusted diluted earnings per share (EPS) of $0.42 on revenues of $5.38 billion. In the same period last…
ThinkstockApproximately 83% of the U.S. population had some form of health insurance coverage in 2012, according to the latest data released jointly by Gallup and Healthways. While this was the first year of improvement…
Wikimedia CommonsJohnson & Johnson (NYSE: JNJ) managed to beat earnings expectations this morning, and the drug and consumer products giant also reaffirmed its earnings guidance for 2013. This morning we noted that we still…
ThinkstockVIVUS, Inc. (NASDAQ: VVUS) has just secured Food and Drug Administration approval of an amendment and modification to the Risk Evaluation and Mitigation Strategy for its weight-loss drug Qsymia. With a recent study published…